AbbVie and Eli Lilly exit UK drug pricing agreement
The Association of British Pharma Industry (ABPI) said it was seeking early talks with the government to set out a new future…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
AbbVie
Abbvie raises sales outlook of two new drugs to more than $17.5 billion in 2025
The company's previous sales outlook for Skyrizi and Rinvoq in 2025 was more than $15 billion
AbbVie and Cugene announce collaboration in autoimmune diseases
Under the terms of the agreement, Cugene will receive an upfront payment of $48.5 million, and will also be eligible to receive…
Dragonfly and AbbVie expand collaboration in oncology and autoimmune disease
Companies to develop additional drug candidates in immune-mediated diseases using Dragonfly's proprietary Tri-specific NK cell…
US FDA extends review period for expanded use of Abbvie’s psoriasis drug
The US Food and Drug Administration (FDA) was reviewing the application for the use of Skyrizi in patients aged 16 years or older…
US FDA approves second indication for Skyrizi to treat adults with active psoriatic arthritis
Skyrizi maintains a dosing regimen for PsA that is consistent with the existing regimen for moderate-to-severe plaque psoriasis…
US FDA approves drugs from AbbVie and Pfizer to treat eczema
AbbVie’s Rinvoq and Pfizer’s Cibinqo have been approved to treat moderate-to-severe eczema, in patients who do not respond to…
AbbVie submits applications for Upadacitinib in to US FDA and EMA
In the trial study, evaluating the efficacy and safety of Upadacitinib in adult patients with nr-axSpA, Upadacitinib met its…
US FDA adds strict safety warnings on arthritis drugs from Pfizer, AbbVie and Lilly
The US Food and Drug Administration's boxed warnings on the labels of Rinvoq , Xeljanz and Olumiant flags the risk of…
FDA grants BTD for Venclexta in combination with azacitidine to treat patients with myelodysplastic…
Every year, approximately 10,000 people are diagnosed with myelodysplastic syndromes (MDS) in the US, and there remains a high…